Impact of COVID-19 on People of Color

by | Jul 22, 2021 | Coronavirus, COVID-19, FDA, Human Factors, Vaccine

As the COVID-19 pandemic hit the United States, people of color were bearing the brunt of the virus. African Americans specifically were more likely to fall ill with the virus, get hospitalized, and die than White patients.

In total, more than 600,000 individuals have died due to the pandemic. Over 178 million worldwide have had some complications with COVID-19. According to a recent study published by JAMA Network Open, researchers aimed to examine the role hospitals had that influenced patient deaths, specifically looking at people of color.

The study analyzed more than 44,000 Medicare Advantage patients with COVID-19 to more than 1,180 hospitals across 41 states. The researchers found that African American patients who were admitted to a hospital with COVID-19 are 11% more likely to die than their White counterparts. This statistic was found after adjusting for patient and clinical characteristics.

The study also ran simulations and found that if those same patients were admitted to the same hospitals as their White counterparts, their health outcomes would be relatively equal.

The virus arrived in the US at a time of social and racial reform, an issue the medical field has been struggling with for years. The pandemic illustrated the inequalities and inequities in the United States that people of color were more likely to have long-standing complications and die due to COVID than their White counterparts.  

The study demonstrates that where individuals live and work influences where they receive medical care; many individuals tend to seek care closer to their homes. For many years, people of color were denied housing and care in certain areas due to redlining, which was meant to keep out certain races out of neighborhoods. Redlining led to segregation in cities and unequal access to resources, like hospitals and jobs.

The researchers mentioned that this study further illustrates the unequal policies that continue in the United States. These policies point towards issues like housing, job security, and insurance, that leave people of color with unequal access to resources, opportunities, health care, and housing. 1

EMMA International has been staying on top of all the breaking COVID-19 news. Contact us at 248-987-4497 or email info@emmainternational.com to get connected with our team of experts today!

1 Liss, S. (2021, June 21). Black patients were more likely to die of COVID-19 largely due to inferior hospitals. MedTech Dive. https://www.medtechdive.com/news/black-patients-more-likely-die-of-covid-19-inferior-hospitals-JAMA/602147/

Abby McVay

Abby McVay

Research Analyst- Ms. McVay is EMMA International’s Research Analyst. She has experience in technical writing and clinical trials in many life science industries. She has experience with many different elements of quality and regulatory compliance. Ms. McVay holds a Bachelor of Science in Psychology from Manchester University as well as a Master of Science in Industrial and Organizational Psychology from Angelo State University.

More Resources

De Novo Classification

De Novo Classification

A device can be registered for the De Novo pathway if there is evidence of the safety and effectiveness of the device and there is not a previously legally marketed predicate device1. When determining if your device can go through the De Novo process there are two pathways available to determine the device classification.
Abbreviated 510k submission

Abbreviated 510k submission

There are three types of 510K, Premarket Notifications, which can be submitted to the Food and Drug Administration (FDA) traditional, abbreviated, and special. Abbreviated and Special 510K submissions can be utilized when the submissions meet the certain factors presented by the FDA. When submitting an abbreviated 510K the submission must include the elements that are identified in 21CFR 807.87 for the information required in a premarket notification submission.
Is your product a medical device?

Is your product a medical device?

Many marketed products are classified as medical devices and you would not even know it. Medical devices range from latex gloves and tongue depressors to respirators and heart valves. To determine if the product is considered a medical device by the Food and Drug Administration (FDA) you will need to analyze if your product meets the definition of a medical device per the Food, Drug, and Cosmetic Act1.

Ready to learn more about working with us?

Pin It on Pinterest

Share This